Search clinical trials for: Immunotherapy targeting GD2

Total 4964 results

University of California, Los Angeles

Unknown

Brain Mechanisms and Targeting Insomnia in Major Depression

Insomnia | Major Depressive Disorder

United States
University of Zurich

Completed

Frequency of Hymenoptera-stings in Patients Under Allergen-Specific Immunotherapy (SIT) (ZU-HVA-001)

Hymenoptera Sting Allergy

Switzerland
ALK-Abelló A/S
Cetero Research, San Antonio

Completed

Exposure Chamber Trial With Cat Immunotherapy

Cat Allergy

Canada
University of South Florida

Completed

Systemic Reactions to Allergen Immunotherapy Amd Skin Testing (chackos)

SYSTEMIC REACTION

United States
EVE Medical Systems Ltd.
Semmelweis University

Unknown

Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss

Abortion, Recurrent

Hungary
Mannkind Corporation

Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Advanced Melanoma | Stage III and IV Melanoma

United States
Hospital Authority, Hong Kong

Unknown

Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Cardiovascular Diseases | Kidney Diseases | Chronic Disease

China
Fred Hutchinson Cancer Center

Completed

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Cancer

United States
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
EVE Medical Systems Ltd.

Unknown

Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)

Premenstrual Syndrome

Israel
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
EVE Medical Systems Ltd.

Unknown

Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel

Premenstrual Syndrome

Israel
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Taipei Medical University WanFang Hospital

Completed

Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers

Lung Cancer
University of Genova

Completed

Sublingual Immunotherapy In Alternaria-Induced Rhinitis

Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata

Italy
West Penn Allegheny Health System
Pennsylvania Allergy and Asthma Research Foundation

Completed

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

Allergy | Perennial Allergic Rhinitis | Seasonal Allergic Rhinitis

United States
Affiris AG

Completed

Long-term Safety and Tolerability of AFFITOPE AD01

Alzheimer's Disease

Austria
Affiris AG

Completed

Long-term Safety and Tolerability of AFFITOPE AD02

Alzheimer's Disease

Austria
University Hospital Tuebingen
Paul Ehrlich Institute, Langen, Germany

Completed

Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) (KS2422-vacc)

Metastatic Breast Cancer

Germany
Clinica Universidad de Navarra, Universidad de...

Unknown

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

Melanoma | Renal Cell Carcinoma | Carcinoma, Hepatocellular

Spain
Fred Hutchinson Cancer Center

Completed

Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma

Cat Allergy

Canada
Artu Biologicals

Completed

Efficacy and Safety of Grass Pollen Sublingual Immunotherapy

Allergic Rhinoconjunctivitis

Bulgaria, Lithuania, Czech Republic, Germany, Hungary, Netherlands, Slovakia
Artu Biologicals

Completed

Long-term Efficacy and Safety Study With Oralgen Grass Pollen

Allergic Rhinoconjunctivitis

Bulgaria, Lithuania, Czech Republic, Germany, Hungary, Netherlands, Slovakia
Artu Biologicals

Unknown

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Allergic Rhinoconjunctivitis

Netherlands, United Kingdom, Germany, Poland, Belgium, France
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Envita Medical Center, Inc.

Suspended

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Glioma | Breast Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Hepatocellular Cancer | Squamous Cell Lung Cancer

United States
University of Zurich
ImVision GmbH, Hannover

Completed

Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial (IVN-CAT-001B)

Allergy to Cat Dander

Switzerland
Pevion Biotech Ltd

Completed

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Chronic Hepatitis C

Switzerland
Stanford University
National Institutes of Health (NIH)

Terminated

Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases

Liver Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Lymphoma

United States
University Hospital, Basel, Switzerland

Completed

Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma

Melanoma

Switzerland
Hamilton Health Sciences Corporation

Completed

Targeting Inflammation in Acute Coronary Syndrome Using Colchicine (COOL)

Acute Coronary Syndrome

Canada
University Hospital Freiburg
Ludwig-Maximilians - University of Munich; University Hospital Heidelberg; University... and other collaborators

Unknown

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma (PRIMAIN)

Primary Non Hodgkin Lymphoma of the Central Nervous System

Germany
Institut National de la Santé Et de la Recherche...

Completed

Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B (RBM99026)

Chronic Hepatitis B

France
University Hospital Carl Gustav Carus

Completed

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Multiple Myeloma | Plasmocytoma

Germany
Radboud University Medical Center
Dutch Cancer Society

Completed

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Melanoma Stage III or IV

Netherlands
Pfizer

Terminated

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Pfizer

Terminated

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States, Germany, Italy
University of Bologna

Unknown

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Myeloblastic Leukemia

Italy
JANSSEN Alzheimer Immunotherapy Research & Development...
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Alzheimer's Disease

United States

Search clinical trials for: Immunotherapy targeting GD2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations